https://www.nasdaq.com/press-release/ac-immune-awarded-two-michael-j.-fox-foundation-grants-to-advance-small-molecule
https://www.nasdaq.com/press-release/ac-immune-announces-interim-phase-1b-2a-data-showing-that-its-aci-35.030-anti-ptau
https://www.nasdaq.com/press-release/ac-immune-announces-late-breaker-presentation-by-genentech-at-ctad-on-phase-2-lauriet
https://www.nasdaq.com/press-release/ac-immune-reports-third-quarter-2021-financial-results-and-provides-corporate-update
https://www.nasdaq.com/press-release/ac-immune-extends-research-collaboration-with-university-of-pennsylvania-focusing-on
https://www.nasdaq.com/press-release/new-data-on-ac-immunes-abeta-and-ptau-clinical-programs-in-alzheimers-disease-to-be
https://www.nasdaq.com/press-release/ac-immune-holds-its-extraordinary-general-meeting-and-appoints-monica-shaw-m.d.-and
https://www.nasdaq.com/press-release/ac-immune-to-present-at-the-jefferies-london-healthcare-conference-2021-10-25
https://www.nasdaq.com/press-release/ac-immune-ceo-andrea-pfeifer-receives-first-sef.womenaward-for-ceo-of-the-year-2021
https://www.nasdaq.com/press-release/ac-immune-to-participate-in-upcoming-virtual-investor-conferences-in-september-2021
https://www.nasdaq.com/press-release/ac-immune-announces-first-positive-cognitive-results-for-a-tau-targeting-monoclonal
https://www.nasdaq.com/press-release/ac-immune-reports-second-quarter-2021-financial-results-and-provides-corporate-update
https://www.nasdaq.com/press-release/ac-immune-presents-full-phase-1b-results-on-anti-abeta-vaccine-and-discusses-its
https://www.nasdaq.com/press-release/ac-immune-acquires-affiris-specific-active-immunotherapy-sait-anti-alpha-synuclein
https://www.nasdaq.com/press-release/ac-immune-announces-strategic-acquisition-of-industry-leading-parkinsons-disease
https://www.nasdaq.com/press-release/ac-immune-holds-its-annual-general-meeting-of-shareholders-2021-06-25
https://www.nasdaq.com/press-release/ac-immune-provides-update-on-alzheimers-disease-vaccine-candidates-targeting
https://www.nasdaq.com/press-release/ac-immune-to-highlight-first-in-class-alzheimers-disease-vaccine-programs-at-upcoming
https://www.nasdaq.com/press-release/ac-immune-announces-expansion-of-phase-1b-2a-phospho-tau-alzheimers-vaccine-trial-and
https://www.nasdaq.com/press-release/ac-immune-reports-first-quarter-2021-financial-results-and-provides-corporate-update
https://www.nasdaq.com/press-release/ac-immune-appoints-experienced-biotech-and-investment-executive-dr.-alan-colowick-to
https://www.nasdaq.com/press-release/ac-immune-hosts-investor-webinar-highlighting-the-power-of-its-morphomertm-platform
https://www.nasdaq.com/press-release/ac-immune-to-host-webinar-highlighting-its-innovative-morphomertm-technology-platform
https://www.nasdaq.com/press-release/ac-immune-reports-full-year-2020-financial-results-and-provides-2021-rd-outlook-2021
https://www.nasdaq.com/press-release/ac-immune-announces-new-clinical-results-in-down-syndrome-and-plans-for-future
https://www.nasdaq.com/press-release/ac-immune-presents-new-preclinical-data-for-therapeutic-and-diagnostic-candidates
https://www.nasdaq.com/press-release/ac-immune-to-present-new-data-from-alpha-synuclein-and-tdp-43-programs-at-the-ad-pdtm
https://www.nasdaq.com/press-release/ac-immune-to-highlight-promising-alzheimers-vaccine-at-the-svb-leerink-10th-annual
https://www.nasdaq.com/press-release/ac-immunes-alzheimers-vaccine-generates-potent-anti-ptau-antibody-response-in-a-phase
https://www.nasdaq.com/press-release/ac-immune-initiates-clinical-study-of-first-in-class-diagnostic-for-parkinsons
https://www.nasdaq.com/press-release/ac-immune-reports-progress-for-therapeutic-programs-targeting-the-nlrp3-inflammasome
https://www.nasdaq.com/press-release/ac-immune-receives-competitive-target-als-foundation-grant-to-accelerate-the
https://www.nasdaq.com/press-release/immunotherapy-pioneer-prof.-carl-h.-june-joins-ac-immunes-board-of-directors-2020-11
https://www.nasdaq.com/press-release/neurologist-and-psychiatrist-prof.-johannes-rolf-streffer-md-joins-ac-immune-sa-as
https://www.nasdaq.com/press-release/ac-immune-reports-q3-2020-financial-results-and-provides-business-update-2020-11-13
https://www.nasdaq.com/press-release/ac-immune-to-provide-strategy-and-pipeline-update-during-jefferies-virtual-london
https://www.nasdaq.com/press-release/ac-immune-and-wuxi-biologics-strengthen-strategic-partnership-to-accelerate-ac
https://www.nasdaq.com/press-release/competitive-eu-grant-supports-collaboration-to-accelerate-development-of-ac-immunes
https://www.nasdaq.com/press-release/ac-immune-reports-top-line-results-from-tauriel-phase-2-trial-evaluating-semorinemab
https://www.nasdaq.com/press-release/ac-immune-to-showcase-anti-tau-portfolio-at-h.c.-wainwright-22nd-annual-global
https://www.nasdaq.com/press-release/ac-immune-reports-q2-2020-financial-results-and-provides-business-update-2020-08-05
https://www.nasdaq.com/press-release/ac-immune-initiates-ind-enabling-studies-for-first-in-class-antibody-targeting-tdp-43
https://www.nasdaq.com/press-release/ac-immune-wins-prestigious-award-to-develop-a-game-changing-parkinsons-diagnostic
https://www.nasdaq.com/press-release/ac-immune-demonstrates-enhanced-performance-of-first-in-class-parkinsons-diagnostic
https://www.nasdaq.com/press-release/ac-immune-to-present-advances-in-two-of-the-companys-world-leading-programs-at-the
https://www.nasdaq.com/press-release/ac-immune-advances-phospho-tau-alzheimers-vaccine-in-phase-1b-2a-study-2020-07-16
https://www.nasdaq.com/press-release/tau-pet-tracer-pi-2620-could-set-new-standards-for-an-improved-diagnosis-of
https://www.nasdaq.com/press-release/ac-immune-announces-results-of-annual-general-meeting-2020-06-26
https://www.nasdaq.com/press-release/ac-immune-ceo-to-showcase-novel-target-programs-at-ubs-global-healthcare-conference
https://www.nasdaq.com/press-release/ac-immune-reports-q1-2020-financial-results-and-provides-business-update-2020-05-04
https://www.nasdaq.com/press-release/ac-immune-presents-the-latest-preclinical-data-on-novel-drug-targets-for
https://www.nasdaq.com/press-release/ac-immune-reports-full-year-2019-financial-results-and-provides-2020-rd-outlook-2020
https://www.nasdaq.com/press-release/ac-immune-receives-second-milestone-and-new-milestone-to-increase-the-potential-deal
https://www.nasdaq.com/press-release/internationally-renowned-neurologist-dr.-juan-fortea-joins-ac-immunes-clinical
https://www.nasdaq.com/press-release/ac-immune-to-present-new-data-demonstrating-the-depth-of-its-neurodegenerative
https://www.nasdaq.com/press-release/ac-immune-to-present-at-jefferies-2019-london-healthcare-conference-2019-11-14
https://www.nasdaq.com/press-release/ac-immune-q3-2019-financial-results-and-business-update-2019-11-13
https://www.nasdaq.com/press-release/ac-immune-hosts-key-opinion-leader-event%3a-untangling-tau-pathology-to-treat
https://www.nasdaq.com/press-release/ac-immune-to-host-key-opinion-leader-event%3a-untangling-tau-pathology-to-treat
https://www.nasdaq.com/press-release/ac-immune-receives-first-milestone-payment-from-lilly-in-small-molecule-tau
